Can GS-101 Prevent Corneal Transplant Rejection?

September 10, 2009

Gene Signal announced the publication of interim phase II data that suggests that the antisense oligonucleotide GS-101 is safe and effective at inhibiting and regressing corneal neovascularization. This study was published in the September 2009 issue of Ophthalmology. The group that received the GS-101 dose of 86 µg/day showed regression in 86% of patients compared with progression of neovascularization which occurred in 100% of the placebo group.

Forty patients who were non-responsive to conventional therapy participated in the study. Four groups of 10 patients were treated for three months comparing three doses of GS-101 twice a day to placebo (10 patients per group). The primary endpoint was measured by the reduction in area covered by pathologic corneal blood vessels measured morphometrically on digitized slit-lamp pictures.

GS-101 was found to be well tolerated in this study.

The company is now conducting an international phase III trial with GS-101 for the prevention of pathologic corneal neovascularization and thereby corneal graft rejection. GS-101 has been granted Orphan Drug status for this indication in Europe.

Read the release.




Jump down to form below to submit your own comments

Trackback URL

Have insights to contribute? Please submit your comment below